Skip to main content
BCAL DIAGNOSTICS LIMITED logo

BCAL DIAGNOSTICS LIMITED — Investor Relations & Filings

Ticker · BDX ISIN · AU0000160921 ASX Professional, scientific and technical activities
Open in API
Filings indexed 247 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country AU Australia
Listing ASX BDX

About BCAL DIAGNOSTICS LIMITED

https://www.bcaldiagnostics.com

BCAL Diagnostics Limited is focused on the development and commercialization of a non-invasive blood test for the early detection of breast cancer. The company's proprietary diagnostic platform utilizes lipidomics and mass spectrometry to identify specific lipid biomarkers associated with the presence of malignancy. This technology aims to provide a highly accurate, cost-effective, and accessible screening tool that complements or serves as an alternative to traditional mammography. By analyzing changes in the lipid profile of a patient's blood, the test is designed to improve detection rates, particularly in younger women and those with dense breast tissue where conventional imaging may be less effective. The company is dedicated to the clinical validation and global implementation of its screening technology to improve patient outcomes through earlier intervention.

Recent filings

Filing Released Lang Actions
BCAL Launches Early Detection Cancer Platform 2 pages 303.8KB
Regulatory Filings Classification · 82% confidence The document is an ASX announcement providing an operational update on referral infrastructure, digital strategy, telehealth launch, and product rollout. It contains no detailed financial statements, disclosures of voting, dividends, or formal report attachments. It is a general regulatory announcement and does not fit into specific categories like earnings release, capital financing, or management changes. Therefore, it falls into the fallback category of Regulatory Filings (RNS).
2026-05-18 English
BCAL Appoints Anne-Louise Arnett as Chief Executive Officer 4 pages 346.7KB
Board/Management Information Classification · 90% confidence The document is an ASX announcement dated 11 May 2026 detailing the appointment of Anne-Louise Arnett as CEO, the transition of the Executive Chair to Non-Executive Chair, and other leadership changes. This is clearly an announcement of changes in senior management rather than financial results or report publication. Therefore, it fits the Board/Management Information category.
2026-05-10 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 531.1KB
Interim / Quarterly Report Classification · 100% confidence The document is an 'Appendix 4C' filing from the Australian Securities Exchange (ASX), which is a mandatory quarterly cash flow report for listed entities. It includes detailed financial tables (cash flow statements) for the quarter ended 31 March 2026, alongside a narrative 'Quarterly Activities Report' explaining the operational highlights. Since it contains substantive financial data and covers a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q3 2026
2026-04-21 English
BCAL Submits MSAC Application for Avantect Pancreatic Test 3 pages 256.4KB
Regulatory Filings
2026-03-30 English
BCAL Accelerates Rollout of Avantect Early Detection Tests 2 pages 245.9KB
Regulatory Filings
2026-03-25 English
Change of Director's Interest Notice 2 pages 196.8KB
Regulatory Filings
2026-03-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.